Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 274Thoracic 3Lymphoid 2Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 1215Triple Negative Breast Neoplasms 284Ovarian Neoplasms 262Carcinoma, Non-Small-Cell Lung 249Colorectal Neoplasms 190Pancreatic Neoplasms 168Stomach Neoplasms 164Neoplasm Metastasis 156Neoplasms 155Lung Neoplasms 144Prostatic Neoplasms 143Melanoma 132Carcinoma, Renal Cell 103Squamous Cell Carcinoma of Head and Neck 102Endometrial Neoplasms 99Head and Neck Neoplasms 88Colonic Neoplasms 82Urinary Bladder Neoplasms 79Uterine Cervical Neoplasms 77Esophageal Neoplasms 76Sarcoma 72Breast Neoplasms, Male 68Small Cell Lung Carcinoma 66Carcinoma, Hepatocellular 60Carcinoma, Ovarian Epithelial 58Kidney Neoplasms 47Carcinoma, Transitional Cell 41Rectal Neoplasms 35Fallopian Tube Neoplasms 34Liver Neoplasms 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × Breast × Clear all
NCT05076591 2024-10-30

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1 Suspended
135 enrolled
BreastGastrointestinalOther solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡